PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR

Cancer immunotherapy focuses on inhibitors of checkpoint proteins, such as programmed death ligand 1 (PD-L1). Unlike RAS-mutated lung cancers, EGFR mutant tumors have a generally low response to immunotherapy. Because treatment outcomes vary by EGFR allele, intrinsic and microenvironmental factors m...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghosh, Soma, Nataraj, Nishanth Belugali, Noronha, Ashish, Patkar, Sushant, Sekar, Arunachalam, Mukherjee, Saptaparna, Winograd-Katz, Sabina, Kramarski, Lior, Verma, Aakanksha, Lindzen, Moshit, Garcia, Diana Drago, Green, Joseph, Eisenberg, Galit, Gil-Henn, Hava, Basu, Arkaprabha, Lender, Yan, Weiss, Shimon, Oren, Moshe, Lotem, Michal, Geiger, Benjamin, Ruppin, Eytan, Yarden, Yosef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170369/
https://www.ncbi.nlm.nih.gov/pubmed/34038737
http://dx.doi.org/10.1016/j.celrep.2021.109181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170369/
https://www.ncbi.nlm.nih.gov/pubmed/34038737
http://dx.doi.org/10.1016/j.celrep.2021.109181

Ejemplares similares